Mavorixafor (1) – Xolremdi®
WHIM syndrome (Warts-Hypogammaglobulinaemia-Immunodeficiency-Myelocathexis syndrome)
Characteristics
| Start date | 01.09.2026 |
|---|---|
| Resolution | 18.02.2027 – active procedure |
| INN | Mavorixafor |
| Brand name | Xolremdi® |
| Pharm. company | Norgine GmbH |
| G-BA Procedure ID | D-1375 |
| Therapeutic area | Other diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions